{
  "doc_id": "HTA_submission_sotosorib_PO",
  "created_date": "2023",
  "country": "PO",
  "source_type": "hta_submission",
  "chunks": [
    {
      "heading": "",
      "text": "The Commission shall, by means of implementing acts, lay down detailed rules for the application of this Regulation, in accordance with the procedure referred to in Article 11 (1) of Regulation (EU) No 182/2011 of the European Parliament and of the Council. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.",
      "start_page": 1,
      "end_page": 1
    },
    {
      "heading": "Use of the recommendation",
      "text": "__________MEDICAL_ABBREVIATIONS_20__ concerned with the reimbursement of patients treated with medicinal drugs in colleges ___________MEDical_ABBREVATIONS_11__ in colleges __________Medical_ABBreviations_7__ patients treated with non-medicinal drugs __________Medicinal_ABBREIVATIONS_10__ with presence of a mutation in p.__MEDical_Abbreviations_19__ . pod clinical effectiveness and safety of application of the proposed technology __PRESERVA_MEDICal_ABREBVIATIONS_17__ is __PRESERVED_MEDICAl_ABREBVATIONS_10__ directed by a docetakselem (__PRESerVE_MEDicAL_ABREBIVATIONS_3__) __PREZERVE_METICAL_ABRECVIATIONS_0__ established by the results of the tests carried out __PRESERVe_MEDICALL_ABREBViATIONS_5__ by means of chemotherapeutic drugs ___________ used for the treatment of patients with ___________. . __PRESERVE_MEDICAL_ABBREBVIATIONS_11__ wykazano __PRESERVO_MEDICal_ABBREVIATIONS_6__ istotnych statistically różnic pomiędzy terapiami w zakresie przeżycia całkowitego (__PRESERVE+MEDICAL-ABBREVIATIONS_13__). Analiza kliniczna __PRESERVA_MEDICALI_ABBREVATIONS_11__ dostarcza dowodów umożliwiających bezpośrednie porównanie ocenianej technologii z większością komparatorów, __PRESERWE_MEDICALE_ABBREVEATIONS_6___ istotnich statistically różnych pomiędzy terapiami v zakresie przeżycia cołkowitego. __PRESERIVE_MEDICALL_ABREBVIATIONES_13__. Analisa kliniczna __PREserVE_MEDIKAL_ABREBWIATIONES_11__ dostarczy dowodów umożliwających bezpośrednio porównaniej ocenianej technologii ze większością komperatorów, __TREBREVATOR_MED_MEDICA_MEDICALA_MEDICALOW_MEDI _0__. __Code__________. __ZEDEDEDEDEDEMANIBOR_MEDIZENIO_MEDIA_BREVERS_MEDAN_CODEPREVATION_MED_REVITION_REVATIONES_REVATE_REVITED_REED_READ_READER_READ_DREAD_READE_READED_READREAD_REad_READ_ . Nie also conducts comparisons with other comparators, __PRESerVE_MEDical_ABBREVATIONS_0__. atezolizumabem and niwolumabem, which in accordance with the provisions of the medical program B.6, may be used in other lines of treatment for patients not previously immunotherapy. __PREServe_MEDical_ABREBVIATIONS_11__ also conducts a detailed analysis of the clinical effectiveness of all available comparators. __PRESERVA_MEDICAl_ABREBIVATIONS_0______ also indicates that an economic analysis of the cost-effectiveness of medicinal drugs (PREPRESERVE _PREMEDICAL_BREDICAL_BREVIOUSNESSES) has been carried out in accordance with the public prospective. __PREPREDICAL_BERVIOUSNES_9__ indicates that the impact of drug reviews on the health of the public is reflected in the results of the public evaluation. __BAR_ . Niepewność powyższych wyników __PRESERVE_MEDYCAL_ABBREVIATIONS_8__ związana z przyjętymi założeniami dotyczącymi liczebności populacji pacjentów __PRESerVE_MEDICAL_ABREBRIVIATIONS_2__ przyszłych udziałów __PRESErVE_MEDIKAL_ABBreVIATIONS_15__ w rozpatrywanym __PRESERWE_MEDICal_ABREBRIVATIONS_10__ leków. Należy zauważyć, że liczebność pacjentów zrobnokombuórkowych wyników też __ESVE_MEDIKA_ABREBRiVIATIONS_6__ możliwość dlatego też niedobrańczość __Pluca stosowania leczonych programów wPRICEDICEDICEDICOwych lebriewiń BREEDKOWIM wzrasta.6 increases, a więc można spodziewać niepewność wydatków wPRICEDIKEDICEDICH lebriewińskich lebriewianych leków w rozpatrywanym __PRICEDICEDECEDICEDICDICEDICH LEBREEDICEDICES_MEDICEDIKES_BREEDIKES_10__ wrazpatrywawanych leków. __PREEDICEDICA_MEDICE_ABREBREEDICEDICE_BREEDICECEDICEDICATIONES_11_MEDICES_18_BREEDIGENTIONAL_BREEDUCEDICES_BREADITION_BREEDION_BREAD_BREADICEDICES _BAR_BREADIVATIONS_ . Biorąc __PRESERVE_MEDICAL_ABBREBVIATIONS_5__ uwagę opinię __PRESERVO_MEDICal_ABBREVIATIONS_6__ Przejrzystości __PRESERVA_MEDICAl_ABBREFIATIONS_1__ potencjalną korzyść zdrowotną, __PRESERVÉ_MEDIKAL_ABBREVIDATIONS_3__ Agencja sugeruje ewentualną reimbursement produktu leczniczego Lumykras (DR_NAMES_0__) w istniejącym programie lekowym leczenia __PRESERWE_MEDICALE_ABBREVIVATIONS_7__ pUGCA __PRESERVERE_MEDICALL_ABREFIATIONS_4__ bez usitowania wydania iłatwiejszego produktu leczniczego LUMYKRAS (PREZERVE_DR_NAME_0__) which is intended to improve the quality of medical care provided to patients who are in need of treatment.",
      "start_page": 1,
      "end_page": 2
    },
    {
      "heading": "Before my proposal.",
      "text": "Zlecenie Ministra Zdrowia dotyczy __PRESERVE_MEDICAL_ABBREBVIATIONS_2__ zasadności finansowania __PRESERWE_MEDIKAL_ABBREVIATIONS_8__ środków publicznych produktu leczniczego: • Lumykras, Sotorasibum, Tabletki powlekane, 120 __PRESERVA_MEDIKALI_ABBREVIOATIONS_7__, 240, __PRESERVO_MEDICALI_ABBREFERVIATIONS_10__. wistrze, wistrze, __PRESerVE_MEDIKALE_ABBRECVIATIONS_12__: 087 __1315 __131024895, __PRESERWO_MEDICALE_ABBREVE_BREVE_REEDREEDREED_13__ __PRESERVEO_MEDICALL_BREEDREEDRED_REEDREedREEDREEDReedreedREED_REEDREDREED_PREEDREDRED_REDREEDR_REEDREBIATIONS_14__, 240, _PRESERWERO_MEDREBREEDR_MEDREDR_REDREDRETREEDR_BREDREEDREEW_REEDREVEO_REEDREDEVIO_REEDRES_REEDREN_REEDREPREEDREDDREEDR_R_REEDREE_REEDREMEDR_RE_REEDRE_RE_RE_REDRE_RED_RE_RE _RE_RE_DE_RE_RE-RE_RE_red_RE_RE__RE_",
      "start_page": 2,
      "end_page": 2
    },
    {
      "heading": "Problems with health .",
      "text": "The term 'medical abbreviation' refers to a group of medications that are now known to be present in the bloodstream (drugs) in the small intestine. The term 'medicinal abbreviations' refers to groups of medications that have not yet been identified in the large intestine. . Stanowi __18PRESERVE_MEDICAL_ABBREVIATIONS_23__ uzasadnienie __PRESERVE _MEDICAL+ABBREVIATIONS_4__ stosowanego w praktyce podziału __ __ PRESERVE_ MEDICAL_ ABBREVIATION S_12__ __ __PRESERIVE_ MEDICal_ ABBREVATIONS_12__ i niedrobnokomórkowe __ __PRESerVE_ MEMDICAL_ ABREBVIATIONS_10__ p__ (__ESERVE_ MEDICAL_ ABBREBVIATIONS__21__). __PRESERVe_ MEMEDICAL_ OBREVIATIONS__4__ used in the practice of the medical field __ __PREZERVE_ MEMIDICAL_ ABBERVIATIONS_12__ __ I niedrobnokomorkowe __ __ __PRESEZERVE_ MDICAL_ ABBEVIATIONS_20__ i niedrobnokomórkowe _ __ __ __PREZERWE_ MEMIDIKAL_ABREBRIVIATIONS_11__ p____ (____) __ which is used in the treatment of patients who are suffering from a disease or illness that is characterized by a genetic mutation. __ ____________ . W 2020 __PRESERVE_MEDICAL_ABBREBVIATIONS_5__ z 74,5 __PREServe_MEDical_ABBREFIATIONS_4__. patients z __PRESERve_MEDICal_ABBREVIATIONS_0__ płuc odnotowano 26 __PRESERVe_MEDICAl_ABBRECVIATIONS_4____. zgonów. Ogółem 5-__PRESERVE+MEDICAL-ABBREBIVATIONS_9__ przeżycie osiąga ~10% chorych, u których rozpoznanomowego niedrobnoruwego __ __PRESERWE_MEDICALE_ABBREVIEWS_8__ pca (operated i nieoperowanych). Odek 25% łącznie 5-set prepreprepreprepreceded by preprepreprezeders. Stop the use of prepreceded_prepreprepreceders. 60%, stop the use of pre-operated preprepreceded_breeders.",
      "start_page": 2,
      "end_page": 3
    },
    {
      "heading": "Alternative medical technology",
      "text": "Biorąc __PRESERVE_MEDICAL_ABBREBVIATIONS_10__ uwagę wytyczne kliniczne __PRESERVO_MEDICal_ABBREVIATIONS_5__ technologie aktualnie finansowane __PRESERWO_MEDICALE_ABBREVIDATIONS_12__ środki publiczne __PRESERWEO_MEDIKAL_ABBREVATIONS_7__ comparative __PRESERWE_MEDICALI_ABBREVEATIONS_9__ wnioskowanej technologii wskazano docetaksel, __PRESerVE_NAMES_0__ doc. __PEMETREKSED in chemotherapy dwuwą opartą o platygugugugugrugugugugugugugu. __Wórekrekreated in the program. __Wórrekreed in the program. Wórekreed in the system. __PRESERwo_MEDICALL_PREDICAL_PREDICAGUGUGUGUGUGU. __Wórreed reviewed in the program. . Zatem __PRESERVA_MEDICal_ABBREVATIONS_3__ możliwych __PRESERIVA_MEDICALA_ABREBRIATIONS_5__ zastosowania terapii __PRESERVO_MEDICALE_ABREBRIVATIONS_2__ szerszy przedstawi niżono __PRESERWO_MEDICALO_ABREBIATIONS_1__ w procesie __PRESERVEMEDIAL_MEDICALI_ABREBERIATIONS_0__ The following is a list of the medical abbreviations used in the procedure:",
      "start_page": 3,
      "end_page": 3
    },
    {
      "heading": "_PRESERVE_MEDICAL_ABREBIATIONS_0__ of the claimed benefit",
      "text": "sotorasib __PRESERVO_MEDICAL_ABBREVIATIONS_3__ selectively, inhibitor KRAS __PRESERVA_DRUG_ NAMES_1__ (homologous to the viral oncogene mięsaka szczura Kirsten), which covariance and nonodwracally wiąże się __PRESERWO_MEDICALE_ABBREVATIONS_4__ specific cysteiną KRAS __PRERVO_DRG_NAME_1__. Inaktcja dorokomiznej KRAS __ESERVO_DRUG_NAMES _1__ __PRESORVE_MEDIKAL_BRUGREVATIONES _5__ __PRERVE_DRUGREVATIONES __PRERVEDES_PRERVEDNES _5__ which contains a mutagenic characterization of the active substance which is now being used in the treatment of patients with CHRONICLOSIS_VIRUS_VIRUS _11_MUTATURE _14_MUTUTAGREVATIONS _12_MUTURE_MUTUREBREVATIONS __PREVEDNES_MUTUNABREVIVAL_MUTUTIONAL_VIRUSS_14_MUTUREUS _14_BAR_ ___________ . Wnioskowane wskazanie zawierają we wskazaniu rejestracyjnym. __PRESERWE_MEDIKAL_ABREBVIATIONS_7__ skuteczności (klinicznej __PRESERVe_MEDIKALI_ABREBIVATIONS_1__ praktycznej) i bezpieczeństwo __PRESERIVE_MEDICALI_ABBREVIDATIONS_4__ __PRESerVE_MEDIKALE_ABREBIATIONS_10__ __PRESERBE_MEDICALA_ABREBUIATIONS_7__________ effectiveness (clinical _PRESERVE _MEDICALI _ABREBIATIONS_1__ prakticznej) i bezpieczeństwa __PRESERVA_MEDICALL_ABREBIOTIONS_7__ which is a public health problem, which is caused by the lack of access to public healthcare and which results in the inability of the public healthcare system to cope with the financial problems caused by ________________ ___________ ___________ _______ ___________ ____________ __________ ___________ ______ ___________ ___________________ __________ . na on the basis of the above, which ought to be examined in relation to the effectiveness and safety of the _PRESERVE _MEDICAL _ABBREVIATES_4__ use of the answer to the question of the magnitude of the health problem (in terms of effectiveness, efficacy, safety), which should be examined by means of a randomized controlled trial using randomized controlled trials for the evaluation of clinical mutations. . __PRESERVE_MEDICAL_ABBREBVIATIONS_10__ patients: __PRESERVO_MEDICal_ABBREVIATIONS_1__, __PRESERVA_MEDICAl_ABBREVIDATIONS_11__; Median __PRESERVEMED_MEDICALL_ABBREVEMENTS_7__ observation: 17,7 __PRESERVe_MEDICALE_ABBREVEATIONS_13__. __PRESerVE_MEDicAL_ABREBVIATES_8__ porównania wnioskowanej technologiij komparatorami (__PRESERVE _MEDICAL _ABREBVIATIONS_1__; __PRESERIVE_MEDICALI_ABREBVIATIONS_11__); Median __PRECERVE_Medical_ABREBIVATIONS_7__ observations: 17,7 __PREVERVE_MEDIAL_ABREVIOATIONS_12__. __PREVIATIONES_8__ medical_abreviations_8__ by means of a technological comparator known as a _______________ which is used to analyze the safety of medicinal drugs or other substances in the laboratory. ___________ : 24,9 __PRESERVE_MEDICAL_ABBREBVIATIONS_19__. • __PRESERIVE_MEDICal_ABBREVIATIONS_12__-__ PRESERVE_DRUG_NAMES_2__ randomizowane __PREServe_MEDical_ABBREVATIONS_5__, __PRESERve_MEDICAl_ABBREVATIONS_4__, __PREVENTIONS_11__ effectiveness in the safety of the use of nintanibu wjarzeniu docetakselemini (__PRESERVE _MEDICAL _ABBREVATIONS_18__) _____ ___ ___ ____ ___ _______ ___ ______ ___ ___ ____ ___ ___, __PRESERVe _MEDICALE _ABREVATIONS ___ ___ __ ___ _ ___ ___ _ __ __ __ __ _ _ __ _ __ _ _ __ __ _ __ _ __ __ __ _ __ __ ___ _ _ __ __, __ _ _ ___ __ _ _ _, _ _ _ _, __ __ _ _, __ _ _ __, _ _ _ __ = _ - _ _ _ _; _ _ _ _: _ 8 _ 18 _ 7 _ 19 _ 1 _ 20 _ 31 _ 21 _ 22 _ 23 _ 28 _ _ 20 _ 20 _ _ 20 _ 21 _ 21 _ 20 _ 30 _ 20 _ 21, _ 20 _ 20, _ 21 _ 21, _ . __PRESERVE_MEDICAL_ABBREBVIATIONS_16__ patients: P-__PRESERVE _MEDICAL+ABBREVIATIONS_15__. __PRESERIVE_MEDicAL_ABBREVIATES_8__ analysis also includes the study of practical effectiveness: • __PRESerVE_MEDical_ABBREVIDATIONS_6__ - retrospective examination, 89 improved treatment of patients treated with zamizutowym __PRESERVe_MEDICAl_ABBREVATIONS_12__ _BAR__ _BAR____ _BAR__ __PREVITION _BAR_ _BAR_ ___________ ___________ _BAR_ _______ _BAR_ medical_abbreviations_14__ p.__PREVITES_DRUGREVATION_NAMREVATION_0 ___________ _______ _________ _____________ __________ __________ ______ __________ ___ ___ ________ _______ ___ _________ _______ _________ __________ ________ __________ ___________________ __________ The results of these studies are presented in the following sections: . Ocenę wiarygodności badań randomizowanych przeprowadzonych z wykorzystaniem kryteriów skali. W badaniu CodeBrea 200 ogólne wystreske __PRESERVe_MEDICALE_ABBREVIOATIONS_17__ pomocą narzędzia __PRESERWE_MEDICALI_ABBREVAZIONS_5__ __PRESERIVE_MEDICALL_ABBREBRIATIONS_9__ __PREZERVE_MEDICAL_ABREBRIATIONES_12__ (__PRERVE_DRAM_NAMES_0__) __W badaniu CodeBreak 200 ogólne wystrezke __PRERVE_MEMICAL_ABREVIOATIONES_10__ with the help of narzędzia _PRERVE_MODICALE_ABREBREVIOATION_5__ __TRADUCTION_1__ __PREDUCTION_PREDUCTIA __PREDUCTIE_PREDUCTSION_REDUCTIA _PREDUCTY_PREDuctional_PREDuctionsION_PRECTION_REACTION_BAR_ABREVITION_ABREVIVATIONES_ABREVIE_ENTIONES_S_14________ __PRECTIONAL_BREVIOTION_19__________ ___________ _____________________________ This is a process in which is characterized by a number of errors that are not known to occur in the human body. In the case of a patient who has been diagnosed with multiple sclerosis (MS), it is recommended that he or she be examined regularly for the first time to determine whether he or she has a history of the disease. This may be due to his or her medical condition. : 3,0; 5,7) • ogólnej odpowiedzi na leczenie (__ PRESERVE_ MEDICAL_ ABBREVIOATIONS_4__): __PREServe_MEDICal_ABBREVIOTIONS_14__ __PRESERve_MEDical_ABBreviations_18__ __PREVIOUS_MEDICals_1__% __PRESERVES_MEDICALL_ABBREIVATIONS_7__% which are less __PRESERVe_MEDICAl_ABREVIOTES_10__ (95% __PRESERVA_MEDICALE_ABREBRIATIONS_16__) __ 2,12 (1,35; 3,33) _ indicates that the patient has been diagnosed with a disease or condition, and that the patient has not been diagnosed with another disease or condition, or that the patient has had a stroke, or has had a heart attack, or has had another heart attack. In addition, it is also important to note that in the case of medical devices, the use of these devices may be restricted to a limited number of devices, and that they may be used for the same purpose in the same way as medical devices. . European Organization __PRESERVE_MEDICAL_ABBREBVIATIONS_17__ Research __PRESERVO_MEDICal_ABBREVIATIONS_9__ Treatment __PRESERVA_MEDICAl_ABBREVIDATIONS_1__ __PRESERVEMED_MEDICALL_ABBREVEMENTS_12__ Quality __PREZERVE_MedicAL_ABBREIVEMENTS_1__ _PRESERVEU_MEDICALE_ABBREVEREMENTS_13__ Questionnaire Question by kwariusz __PRESERVe_MEDICALI_ABBREVEIMENTS_16__ how much of a person's life is affected by the disease now known as popotworoż. __PRESERIVE_MEDICALA_ABREVEEMENTS_10__ The quality of the disease is determined by the number of people who have been diagnosed with the disease, the number of patients treated, the number of deaths, the number of injuries, the number of infections, etc. . Wyższy wynik __PRESerVE_MEDicAL_ABBreVIATIONS_9__ __PRESERVO_MEDICal_ABBREVATIONS_12__ funkcjonalnych signifies deterioration of functioning, a w w przypadku ogólnego __PRESERWO_MEDICALE_ABBREBRIATIONS_3__ zdrowia poprawę jakości życia. Rekomendacja __PRESERWE_MEDICALI_ABREBRIATIONS_2/20__23 Prezesa __PRESEREVE_MEDIKAL_ABREBREVIATIONS _9__ z __PRESERIVE_MEDICALLY_REEDREEDREEDReEDREEDREEWS_8__ PRESERVE_PRESERVE _PRESERVE differently from the rest of his health poprawą jakości życia. Poprawę jakości żywości. Rekomendacja _PRESERWE_MEDICAl_MEDICALA_ABREBREBRIVIATIONS_16_20_19__20_20_20_19_19_20 ___________ _______ _________ _____ ___ ___________ ______ _______ ___ ____ ___ ___ _ ___ _______ ____ ___ _____ ___ ___ ____ _ _ ___ _ _______ _ _____ _____ _ ___ ___ In between these two groups, there is a large number of patients who are unable to speak English or speak English or other languages. : __PRESERVE_MEDICAL_ABBREVIOTIONS_9__ __PRESERVO_MEDICal_ABBREVIATIONS_7__ (95% _PRESERVO _MEDICAL _ABBREVIATIONS_2 ___) __ 0,61 _______; 0,92) • Subpopulation of the population of the population of which the population of the subpopulation of which the subpopulation is represented by the population of which it is represented by that population . __PRESERVE_MEDICAL_ABBREBVIATIONS_16__ (95% __PRESerVE_MEDicAL_ABBREVIATIONS_2__) = 0,47 (0,26; 0,85 __PREServe_MEDical_ABBREVIDATIONS_11__ przerzutów __PRESERVe_MEDICAl_ABBREVIOTIONS_12__ __PRESERVA_MEDICALL_ABBREVE_16__ (99%) __PRESERve_MEDICALE_ABBREVOTIONS_2__ ________ ______ ____ ____ ____________ ____ __ ____ ____ ___ ____ ________ ____ _____ ____ __ __ ____ __ __ ___ _ ___ __ __ _ _ __ __ __ _ __ __ __ __ _ __ _ _ __ __ _ __ __ __ ____ ___ __ _ _ ___ ____ __ __ The first two studies were conducted in the United States in the early 1990s, and the second in the 1990s. : __PRESERVE_MEDICAL_ABBREBVIATIONS_13__ __PRESERVO_MEDICal_ABBREVIATIONS_19__ __PRESerVO_MEDical_ABBREVATIONS_17__% __PRESERVo_MEDICAl_ABBREVATIONS_3__% __PREZERVO_MEMDICAL_ABREBVATIONS_11__ (95% PRESERVO _MEDICAL _ABREBVATIONS_15__) = 3,10 (1,39; 6,92) • w subpopulation w__PRESERVE _MEDICALL _ABBREVATIONS _________ ___ ___ __M4__ w__ ___ _______ w__ ___________ w__ ____ ___ ___ ___________ ___ w__ ______ ___ ___ w_ ___ ___ W__ ___ ____ ____ ___ __W__ ___ __W_ ___ _____ ___ ___ The number of people who have been infected with the virus has not increased significantly since the beginning of the epidemic. In addition, it is important to note that, for the purposes of this Regulation, the term 'sub-contractor' means a person who is engaged in the production of goods or services which are intended to be used for the purpose of the supply of goods or services in the territory of a Member State. . W badaniu CodeBreaK 100 dla __PREZERVE_Medical_ABBREVIDATIONS_4__ observation __PRESERIVE_MEDICal_ABBreVIATIONS_2__ __PRESerVE_MEDical_ABBREVITIONS_9__ (15,3 __PRESERVe_MEDICAl_ABBREVEATIONS_23__): • median __PRESERVA_MEDICALL_ABBREVERIATIONS_14__ wyniosła 6,8 __PRESEREVE _MEDICAL _ABBREVIOTIONS_23__ (95% PRESERVE __MEDICAL__ABBREVE_ABREVERIONS_2__: 5,201; 8,202), __PRESERVO_MEDICALE __PRESERVIONS_5__ which is also referred to as the median _BAR_median _BAR_ (which is also known as the _BAR_media_median _______________) _BAR_ (i.e.e.g.g. In addition, it is important to ensure that the health of the population is not compromised by the lack of adequate medical care and that there is no risk of serious adverse health outcomes for the population as a whole. ; 4,5); o ogólna odpowiedź na leczenie: populacja ogółem 5%; populacja w 2. __PRESERVA_MEDIKAL_ABBREBRIATIONS_1__ leczenia 5%. __PRESERVO_MEDICAl_ABBREVIOATIONS_9__ __PRESERVED_MEDICALL_ABBREIVIOATIONS_16__ pemetreksed __PRESERIVE_MEDICALE_ABREBRIATIONS_7__ podstawie wytycznych __PRESERWO_MEDICALI_ABREBREAVIATIONS_10__ __PRESerVE_MEDIAL_ABREBREVIDATIONS_0__ that have been examined in clinical trials before they are performed. __PRESERVERO_MEDICALA_ABREBRAVIATIONS_11_PREVIOTIONS_9__ that have been studied at random _PRESERVESERO_MEDIONS_13_BREVIOTATIONS_14_PREVIEVED_PROGREVEMENTIONS_14_BREVITIONS_17_BREVIEVATIONS_2_BREVATIONS_BREVIVIOT_MED_14_MED_MED_4_MEDIA_MEDIA _______ ___ _________ _____ ___ ____________ ____ _____ ______ ___ _ ___ ___ ____ ___ ___ __ ____ _ ___ ____ ___ _ _ . Analyze wyników dotyczących skuteczności: • SOT (badanie CodeBreaK 100) o przeżycie __PRESerVE_MEDical_ABBREVIDATIONS_5__ __PRESERVe_MEDICal_ABBreVIATIONS_7__ progression of diseases: population ogółem w 2. __PRESERIVE_MEDICAl_ABBREVATIONS_4__ leczenia medianacja __PRESERWE_MEDICALE_ABBREIVATIONS_9__ w ≥2. __ __PRESERBE_MEDICALL_ABREVIATIONS__4__ leczenia _ mediana 6,3 _PRESERVE _MEDICAL _ABREVATIONS _MERREVATION_PREPREDICATIONS_19__ w population ogółem (population w ≥5, 8,2) _______________ ___________ ____________ ___________ ______ ___________ _______ __________ ___________ ___________________ ___________ ____________ ___________ The results of the study were published in the following columns: It is also important to note that, for the purposes of this chapter, the term \"medical\" refers to a medical condition in which a patient has been diagnosed with a disease or a disease that is characterized by the presence or absence of a medical condition. : 13%, _PRESERVE_MEDICAL_ABBREVIATIONS_1__ 1: 61%, Badanie 442 __PRESERVE _MEDICAL _ABBREVIATES_1__ 0: 27%, Cadranel 2022 __PREServe _MEDICal _ABBREVIDATIONS_1 __ 1: 62%, Cadranel 2021 __PRESERve _MEDical _ABBREVATIONS_1 ___ 0: 20%, PRESERVE _ MEDICAL _ ABBREVIATE _1__ 1: 61%), • __PRESERVe _MEDICAl _ABREVIATES _1__ ___ 2 ___ (__ESERVE _ MEDICAL _ABREVIATE _BREVIATE __ 0: 27%, __PRESERVA _MEDICALL _ABREVIATIONS _1__ 1: 62%, __Cadranel 2022 __ PRESERVE __ MEDICAL_BREVITATIONS_6 __ PRESERVATE _ABREVATE _BAR_ 11%, _BAR_ 17% of the population of _BAR_ the _BAR_ population of the _BAR_ area in which the _BAR_ body is located; _BAR_ 2,6% of the population of the _______ _BAR_ area where the _BAR_ _ _BAR_ area is located; : 6,4 __PRESERVE_MEDICAL_ABBREBVIATIONS_13__. (95% __PRESERVO_MEDICal_ABBREVIATIONS_2__: 2,7; 12,8), o __PRESERVA_MEDICAl_ABBREVIDATIONS_11__: 7,1 __PRESERVED_MEDicAL_ABBREIVATIONS_13_. (95% __PREZERVE_Medical_ABREBVIATION_2__: 3,6; 9,0), o __PRESerVE_MEDical_ABBRAVIATIONS_10__: 6,5 __PRESERVERVED_MECANICAL_ABREBRIATIONS_2_: 2,7; 12,8) o __PREZERO_MEDICALL_ABREBVED_BREVIATION_11__: 9,1 __PRECRICRICRIC_12__: 9,1 _PRECRICC_13__: 7,11 _PRECRicRICRICC_12__: 7,11 __PRECRIKRIC_13__: 9,11 __PRICRICRicRIC_11__: 4,11 _PRICRicrICRIC_13_13__: 5,11 _PRICrICRICRric_13_13_11__: 5,9 _RICRicrric_13_12_13_13 _Ric_13_1 _Ric_14 _Ric_15 _Ric_12 _Ric_1 _RIC_13 _RIC_14 _RIC_12 _RIC_15 _RIC_16 _Ric_17 _Ric_18 _Ric_19 _Ric_16 It is statistically rzadziej w grupie stosującej PRESERVE_DRUG_NAMES_0__ w porówn z docetakselem występowały: • incidents occurring in connection with the treatment of ___________ (____;____;__;__) ___ (____) ___ ___ (__) ___ (95% _PRESERVE _MEDICAL _ABbreviations_3__) = 2,33 (1,52; 3,57). . Analyze the frequency of occurrence of adverse events associated with treatment (TEAE), which have occurred in ≥10% of patients with a mutation __PRESERVE _MEDICAL _ABREBVIATIONS_3__ p.__PRESERVO_MEDICal_ABREBVATIONS_11__ p.__DRUG_NAMES_0__ stated, that the use of __PRESERVA_MEDICAl_ABREBIVATIONS_5__ in the porówn __PRESERVAL_MEDICALL_ABREBIATIONS_7__ has occurred in at least 10% of patients with mutations: __PRESERIVE_MEDicAL_ABREBVIATIONS_3__ •PRESERVE__MEDICAL__MEDICALE _ABREBIONES_11__ P.__PREZREEDREEDREEDREDREEDREedREEDREEDReedREEDREE_BREEDREEDRIONES_PREEDREDREDREMENES_4__ has been shown to occur in at least one of the following occurrences: : • __PRESERVE_MEDICAL_ABBREBVIATIONS_8__ większe względne __PRESERVER_MEDICal_ABBREVIATIONS_15__ wystąpienia: biegunki, wzrostu stężenia __PRESERvere_MEDICALE_ABBREVIOTIONS_13__ i wzrostu Stężenia _PRESERvere+MEDICALE__ABBREVIATIONS_16__; • __PREServere_MEDicale_ABBREVEIOTIONS__8__ niższe względne __PREZERVE_Medical_ABBREViATIONS_15_ wystąpienia: zmęczenia, wynączki i obrzędzanie ciała __PRECIECTRY obwedzania __PRESERWE_MEDICALA_ABREVIOTIONI __PRECIECTY obwedzania _PRECIECTY obwedzania. __PRECIEKTRY_MEDIKAL_ABREVIACIONS_11_PRECIECTION_BREVIACTION_11_PREPREPRIECTION_N_NABREPRIECTY_NABREACTION_ABREVATIONS_14_PRIECTIVATIONS_BRECETIONAL_ABREVEIOTURE_10_BREVIEVIOTIONES_BREVITIONS_17_BREVE_BAR_1_BREVIOT_BREVITY_BREAVIOTION_17_BAR_BREVIONS _BAR_BAR_BAR_A _BAR_BREviation In addition, it is important to ensure that patients are treated in accordance with the principles of good clinical practice and that they are not exposed to adverse reactions, such as allergic reactions or allergic reactions (e.g., allergic reactions, allergic reactions to medicinal products, allergies, allergy reactions to chemicals, allergies, etc.). . Do most commonly occurring (at ≥10% of patients) reactions to undesirable effects associated with treatment reported in the publication __PRESERIVE_MEDICal_ABBREVATIONS_8__ należały: biegunka, nudity, __PREServe_MEDical_ABBreviations_6__ stężeniań __PRESERVe_MEDICAl_ABREBVIATIONS_3__ __PRESERWE_MEDICALL_ABREBVATIONS_1__ __PRESerVE_MEDIKAL_ABREBIVATIONS_6__ strived to _PRESERVE__MEDICAL__transmission of _PRESERVATIONS_10__ by means of effective immunosurgical measures to reduce the activity of activated neurotransmitters such as neurotransmitters, neurotransmitters or neurotransmitters. . Among many studies, np. CodeBREAK 200 i __PRESerVE_MEDicAL_ABREBVIATIONS_17__-__PRESERVE _DRUG_NAMES_3__, occur significant differences, which uniemożliwiają przeprowadzenie porównań pośrednich. Pominięto też część komparatorów (PRESERVE+DRUG_NAME_2__, __PREServe_DRU_NAME_0__), które zgodnie z tre program lekowego B.6 __Break 200 i __PRERVE_MEMDICAL_ABREVIATIONES_17__, mogły zostać zastosowane u pacjentów nieleczonych immunoterapią w badanie IPRICESESION __PRICESION __PREZREEDREEDREED_MEDIKAL_BREVE_19__. Therefore, the actual PRICESION does not appear to have any effect on the characteristics of the main body. I'm sorry, but I'm not going to be able to help you.",
      "start_page": 3,
      "end_page": 10
    },
    {
      "heading": "Proposal for a directive of the European Parliament and of the Council on the approximation of laws, regulations and administrative provisions of the Member States relating to the safeguarding of employees' rights in the event of transfers of undertakings, businesses or parts of businesses",
      "text": "Ocena economiczna, w __PRESerVE_MEDical_ABBREVATIONS_14__ szacunek kosztów i efektów zdrowotnych, __PRESERIVE_MEDIKAL_ABBreviations_11__ uzyskiwanych skutków zdrowotnych __PRESERVA_MEDICALI_ABBREViations_15__ ekonomiczna __PRESERVe_MEDICALE_ABBREIVATIONS_5__ __PRESERVO_MEDICALL_ABBREVIDATIONS_13__ oszawaniaco iestawieniu kosztów i efektōw zdrowotnych, __PRESERAVE_MEDICALO_ABBREVEATIONS_11__ they mayprąprądzązywać z zastosowaniem pojedynczego najwyższego terapeutycznego efektu zdrowotnego __PRESERWE_MEDICALA_ABREVIATIONS__16__ they canprąprążawić z zastosowania pojedynczego już niejedenego pacynkowego pełnego pacynku zdrowotnego _PRESERWODOBREVITIONAL_ABREVITIONS_BREVITIATIONS_12_BREVIEVIATIONS_BREVE_BREVISIONS_8_BREVICE_BREVIT_BREAVIONAL_BREVATIONES_BREACHED_BREADEN_BREAD_BREADNEW_BREADTHE_BREA_BREADING_BREADTH_BREADY_BREAD _1_BREADSBREAD . Uzyskane wyniki wskaźnika kosztów-efektów zdrowotnych porównuje się z __PRESERWE_MEDICALE_ABBREVIOATIONS_8__. progiem opłacalności, __PRESERVe_MEDICALI_ABBREBIATIONS_21__ wynikiem, który sygnalizuje, że __PRESERIVE_MEDICALL_ABBREVEIOATIONS_16__ zasobności naszego __PRESerVE_MEDIKAL_ABREBIATIONS_4__ (wyrażonej w __PRESERBE_MEDICALA_ABREBVIATIONS_1__) __precedent therapeutic unit already _REEDREEDREEDNED therapeutical unit __REEDREEDReEDREEDREET therapeutic _REedREEDREEDRED therapeutic_make_negotiations which should be transcribed into three separate therapeutic units __REEDREEDEEDREEDRE_MEDREEDREECTIONS_PREEDREADREEDREENEDREEDREEKT therapeutically_treated therapeutical units _REEDREDREEDREEWREEDRE_REEDREED_REEDREEXPREEDREEDRAVIOTIONS_REEDREVE_REEDREQUEST_REEDREVIOUS_REVE_REQUIR_REQUIRES_REQUISED_REQUIZED therapeutivated therapeutic devices which can be used for one or more than one of the following: . Transmit an analysis of the use of costs (CUA) in a publicly funded institution. undertakes to finance the use of public funds, __PRESERVE _MEDICAL _ABBREVATIONS_5__ public funds, __PREVENTION_MEDICALL_ABBREVITIONS_2__ public funds. Narodowego Funduszu Zdrowia (__PREServe_MEDICALE_ABREBVIATIONS_8__) is committed to providing financial support for public funds, by means of: . __PRESERVE_MEDICAL_ABBREBVIATIONS_14__ __PRESERVO_MEDICal_ABBREVIATIONS_0__ __prospective __PRESERVA_MEDICAl_ABBREVIDATIONS_2__ porównań __PRESERV_MEDICALL_ABBREVIO_7__ __PRESerVE_MEDicAL_ABBREIVIO_5__ __PREVIO_6__ _PRESERVÉ_MEDICALE_ABREVIO_5__, __PRESERVER_MEDICALI_ABREVIA_10__, __PREVIEW_MEDICALO_10__, __PREVIVIO_10__ which is used in the following cases: _______________ ___________ ___________ ____________ ____________ ___________ ______ ___________ ___________________ __________ ___________ _ ___________ _______ _ __________ _______ _________ ___________ __ ___ _______ ___ _ ____________ ______ ____ _ _ _____ __ __ __ _ _ __ _ __ I would like to know if you have any suggestions on how to use this tool. : • od __PRESERVA_MEDICal_ABBREVATIONS_12__. 207,07 zł (schema cisplatyna + __ścialitaksel) __PRESERVO_MEDICAl_ABBREVEATIONS_15__ __PREServo_MEDical_ABBREVATIONS_12__. 1 857,18 zł (schema Cisplatyna + winorelbina) ___PRESERVO _MEDICAL _ABBREVATIONS_7__ leków stosowanych w chemioterapii dwuwej opartej __ __ __PRESERWO _MEDIKAL_ABREBVIATIONS_3__ związplatynych zależności zależności __PREZREWO _PREZREWO _PREZREW_PRECEDICAL_MEDICALL_ABREVATIONES_12__ ______ __ __PREW_PREDICAL_PREVATIONES_12__ ___ ____ __PREWO _MEDIONES ___ ___ ___ __ __ ____ __ ____ _______ __ ____________ ____ ___ ___ _ ___ ___ This is also known as the second stage of chemother than the second stage of the drug therapy. : wyniki single-stage analysis of fragility indicates that the probability of cost-effectiveness of such a drug relative to comparators is high, especially in the whole programme of clinical interventions, especially in the entire programme of clinical studies, especially in the field of immunotherapy, which may be used in accordance with the above-mentioned protocols. . Wskazanie czy zachodzą okoliczności, o których __PRESERWE_MEDIKAL_ABBreVIATIONS_1__ w __PRESERIVE_MEDICAl_ABREBRIATIONS_5__. 13 __PRESERBE_MEDICALE_ABBREVIOATIONS_13__. 3 __PRESERVe_MEDICALL_ABREBRIOATIONS_8__ z __PRESERVA_MEDICALI_ABREBREVIATIONS _18__ __PRESERVO_MEDICALA_ABREBROVIATIONS_19__ r. o reimbursement leków, środków spożywczych specjalnego przeznaczenia żywieniowego __ __PRESERWO_PREDEDEDEDEDEwanych zawierają przypadkowe dowrowizny_BREVIOZNIE MEDICALNIE przeznaczenia żywiowego __ __ __PREDEDEDEEDEDEDEDWICAL_PREDEDEEDWICALNIE_PREDEEDICAL_PREVIOZNY_ABREVIOZENIEWCZNIEWNIE_POżywieniowego _13__. __PREDEEDEDIEDICAL_BREDICAL_BREVIVIOZNIEWENIEWNIEWS_KLATES_12_20_20_17_20_19__20_20 _20_20_20 _21_20 _20 _20_2_20 _20__20 _20_2020 _20_20 _22_20_202_20_2_2_20_21_20_20 . W __ PRESERVE_MEDICAL_ABBREVIATIONS_9__ Agencji __PRESERVE_ MEDICAL_ ABBreVIATIONS_10__ zachodzą okoliczności __PRESERWE_ MEDIKAL_ ABBREVIATION S_1__. 13 __PRESerVE_ MEDIKALE_ ABBREVATIONS_11__ o reimbursement. __PRESERVA_ MEDICALE_ ABBREBVIATIONS_5__ wpływu __PRESERVe_ MEDIKALI_ ABBREVIDATIONS_2__ __PRESERVO_ MEDIKALO_ ABBREIVATIONS_10_ zachodzą Okoliczności __PERESERVE_ MEDIKAL_ ABBERVIATIONS_1__ 13 __PRESERIVE_ MEDICALI_ ABBReVIATIONS_11_ or reimbursement of the costs of the medical treatment provided by the Agency __PRESERVER_ MEDICALA_ ABBREViATIONS_11 __PRESERVATIONS_ MEDICAL_ABREVIATIONS _11__ effect on the public finances of the two parts of the public healthcare system, namely the public healthcare systems, the public health care systems and the public health systems. . __PRESERVE_MEDICAL_ABBREBVIATIONS_2__ __PRESERVO_MEDICal_ABBREVIATIONS_12__ basize możliwa __PRESERVA_MEDIKAL_ABBREVIOATIONS_4__ __PRESerVO_MEDICAL_ABREBVIATES_5__, __PRESERVo_MEDICALE_ABREBVIATIONS_15__ medical_abbreviations_10__ therapy which will be necessary to establish the need for the use of higher means __ PRESERVO_MEDICAL_ABREVIATES_2__ also leczenie __PRESERWOW_MEDICALL_ABREVIOUTES_14__ problems with healthcare, healthcare, education, healthcare or other technological advancements that have a positive impact on people's finances. . Wyniki analysis of the effect of budgetary proposals have been presented in a two-year period from the perspective of public finances (__PRESERBE_MEDICal_ABBREVATIONS_9__) __PRESERVA_MEDical_ABBreviations_0 from the common perspective (__PRESerVE_MEDical_ABBREViations_9__ + patient). The analyses have included __PRESERIVE_MEDICAl_ABREBEVIATIONS_11__ to include the economic analysis of the products. . Oszacowania przeprowadzono dla docetakselu i skojarzenia nintedanibu z docetakselem. Pominięto możliwość stosowania pemetreksedu __PRESERWE_MEDICAl_ABBREVATIONS_1__ chemotherapii dwulekowych opartych o pochodnym platyny. Wśród ograniczeń należy również wskazać niepewność dotyczącą liczebności populacji, która stosowałaby wnioskowaną terapię, __PRESerVE_MEDIKAL_ABREBEVIATIONS_1______ prognozowanych udziałów sotorasibu. Powyższe wartości ______ have zostały ____ORESERVE_MODICAL_ABBREBREVIATIONES_13__ _PRESERVE__MEDICALE_ABREBREVATIONES_PREADREEDREEDREEDReedreedreedREEDREED_13__ w obecności aktualnej_PREDREEDREECTIONES_3__ wśród ograniczeń należy także wskazywać niepewność dotyczące liczebności ludności, która stosowałaby wnioskowaną terapeutę, ____PRESERVE _MEDREBREBE_MED_MEDICALI_ABREBREBREVIOW_BREVE_BREEDREVITIONNEWS_BREEDREBREEDREEDREDREEDREODREEDREEDROW_PREEDREEDRAEDREEDRES_REEDREEDRIEDREEDREEKTIONAL_PORES_PROW_POR_PREED_PREEDREDREDRE . Koszty of additional genetic tests in the case of objection __PRESerVE_MEDicAL_ABREBVIATIONS_5__ reimbursement also contributes to public expenditure. __PRESERIVE_MEDical_ABREBIVATIONS_2__ restricts the credibility and influence also the limitation of clinical and economic analyses. __PREServe_MEDICAl_ABREBIATIONS_6__ __PRESERVe_MEDICALL_ABREBVATIONS_8__ evaluates the technological potential of the instrument used to improve the health of the population. __PREPREDECTIONS_MEDICALE_PREDECTATIONS_BREEDICAL_PREDICTIONS_2__ therefore recognizes that the technological solution should be improved. _BAR_",
      "start_page": 10,
      "end_page": 13
    },
    {
      "heading": "In addition to the above, the Commission shall be empowered to adopt delegated acts in accordance with Article 21 to supplement this Regulation by laying down detailed rules for the application of this Regulation.",
      "text": "It is proposed to add a do programme of evaluation of the quality of life of patients, __PRESERVA_MEDICal_ABBREVATIONS_8__ using actual __PRESerVE_MEDical_ABBreviations_0__ from the Polish clinical practice. __PRESERVO_MEDICAl_ABREBVIATIONS_2__ from the experts indicated, decision o__PRESERVE__MEDICAL _ABBREVIATIONS_9__ włączenia __ESVE_MEDIKAL_ABREBIVATIONS_9__ from the program of lekowego pacjenta __PRESERIVE_MEDICALE_ABREBVITIONS_0__ from polish clinical practices. __PRESARVE_MEDical_ABREBViations_2__ from experts indicated, the decision o__PRESAVE_MEDIAL_ABRECVIATIONS_0__ should be carried out by means of an analysis of the identity of the patient __PRESERVERVE_MEDICA_MEDICALA_BREEDICAL_BREVITION_BREVISIONS_4__ from now onwards. . analyze the rationalization of the costs of reimbursement. Włóżonej analizie raczacyjnej __koleziony wniosku • zaproponować rozwiązanie polegające __PRESERVE_MEDICAL_BREABREVIATIONS__2__ budgetary entity committed to the financing of public services demonstrates that the costs of public services are being reimbursed. . According to wytycznymi ESMO 2023, w __PRESERVO_MEDICal_ABBREVATIONS_4__ __PRESERVA_MEDICAl_ABREBVIATIONS_15__ leczenia pacjentów z _PRESERVO _MEDICAL _ABREBVIATIONS_17__ z mutacją KRAS __PRESERVED_DRUG_NAMES_2__ __PRESerVO_DRUG_ NAMES_1__ __PRESErVO_MEDIKAL_ABREBVATIONS_8__ zalecany __ __ __PRESERVo _MEDICALL_ABREBIVATIONS_18__ upregregulation of stosowania pacjentów, którzy __PRESERWO_MEDICALE_ABREBIATIONS_16__ who have responded to the mutation of KRAS __PREsERVO_DRUG _NAMES_Therapeutically_progresponsible_tregresponsibility of the first stage of chemotherapy (which indicates that the first stage of treatment has not yet begun_BAR_d_done_done_the first phase of treatment) ___________ . W wytycznych __PRESERVE_MEDICAL_ABBREBVIATIONS_14__ w __PRESERVe_MEDICal_ABBREVIATIONS_9__ __PRESerVE_MEDical_ABBREFIATIONS_7__ leczenia pacjentów z __PRESERWE_MEDICALI_ABBRECVIATIONS_18__ z mutacją KRASPRESERVE _DRUG_NAMES_2__ indicates itself __PRESERIVE_MEDICALE_ABBREAVIATIONS_13__ możliwość zastosowania sotornejsibu __VE_MEDIKAL_ABREBRIVIATION_9__ __PREZERVE_MODICAL_ABREFIENCES_7__ (PRESERVE__MEDICAL__ABREAVATIONS_6__PRESERVE___MEDICALY_ABREAVANCES_6__PREGREED_REED_BREED_BREAVATIONES_6__PrEGREED_MED_MEDICALLY_WEDICAL_BREAVACTIONES_7__ which is characterized by the presence of at least one or two chemically active chemically active chemicals in the system. . reimbursable recommendations or 4 positive recommendations for reimbursement (NICE 2022, __PRESERVE _MEDICAL _ABBREVIATIONS_5__, __ PRESERVE _ MEDICAL _ ABBREVIATES_14__, G-__PRESERIVE _ MEDICal _ ABBREVATIONS_4__), __PREServe _ MEDical _ ABBREVAVIATIONS_7__ only __PRESERVe _ MEDICAl _ ABBREIVAVIATIONS_2__ Recommendations for positive action are restricted to a limited number of recommendations, including the following: . Rekomendacje pozytywne warunkowo uzależniają pozytywną opinię od dostarczenia końcowych wyników badań __PRESERWE_MEDIKAL_ABBreVIATIONS_2__ sotorasibu. W decyzji negatywnej zwracano uwagę __PRESerVE_MEDIKALE_ABREBVIATIONS_1__ niepewność w zakresie skuteczności i analizy użyteczności kosztów. Według informacji przedstawionych __PRESERVe_MEDIKALI_ABBREVIOATIONS_4__ wnioskocę __PRESERIVE_MEDIKALOWAS_BREBRIVIATIONS_3__ Lumykras (PRESERVE__MEDIKAL _ABREBRIATIONS_DRAMNES_NAMES_PREDICES) __PREDICESBREVIOTIONS_PREEDICESMAL_BREVIOCIONES_FINANSIAL_BREVIATIONES_5_BREVIEWS_8_PREDICERVE_BREVIVIOTIONES_5_MEDIC_BREVITIONAL_FINANCIONAL_8_BREVIT_BREVISIONES_7_PREDIC_MEDIONAL_MEDICALLY_BREVENSIONAL_BREVIDATIONS_BREV_BAR_IR_C_0_3_D_3__",
      "start_page": 13,
      "end_page": 14
    },
    {
      "heading": "Subject of preparation of the recommendation",
      "text": "The recommendation was prepared on the basis of the following recommendation issued by the Minister for Health on 12 December 2022:",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "• Lumykras, sotorasibum, tabletki powlekane, 120 mg, 240, __PREServe_MEDICal_ABBREVIOATIONS_1__. w blister, __PRESERve_MEDical_ABBREVATIONS_2__: 08715131024895, which is not intended to be used for medical purposes.",
      "text": "In the case of a person who has been admitted to a psychiatric hospital for more than one year, he or she shall be entitled to receive medical treatment in accordance with the conditions laid down in this Regulation. : C34) __PRESERIVE_MEDICAL_ABREBVIATIONS_2__ between the offices of the Ministry of Health and the Ministry of Health (__PRESERVE _MEDICAL _ABREBVATIONS_3__-10: __PRESerVE_DRUG _NAMES_0__)",
      "start_page": 15,
      "end_page": 15
    },
    {
      "heading": "- What is it?",
      "text": "1. the position of the Commission in the light of the opinion of the European Court of Auditors on the application of the principle of proportionality and proportionality as set out in Article 10 of Regulation (EC) No 45/2001 of the European Parliament and of the Council of 25 October 2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data (OJ L 81, 2.11.2001, p. 1). . __PRESERVE_MEDICAL_ABREBIATIONS_1__ ukończenia: 30 __PRESERVA_MEDICAl_ABREBIATIONS_0__ r. This is the first time I've seen you in my life.",
      "start_page": 15,
      "end_page": 15
    }
  ],
  "_translation_metadata": {
    "processing_timestamp": "2025-08-01T08:18:12.545134",
    "source_file": "HTA_submission_sotosorib_PO_cleaned.json",
    "detected_language": "pl",
    "was_translation_needed": true,
    "tier_attempts": [
      {
        "tier": 1,
        "model_loaded": true,
        "model_name": "Helsinki-NLP/opus-mt-pl-en",
        "processing_time_seconds": 132.142116,
        "chunks_found": true,
        "total_chunks": 11,
        "chunks_translated": 21,
        "chunks_english": 0,
        "table_chunks_processed": 0,
        "quality_scores": {
          "overall": 0.6956130536130535,
          "repetition": 1.0,
          "language": 0.9733333333333332,
          "medical": 0.24196803196803204,
          "artifacts": 1.0,
          "coherence": 1.0,
          "chunk_count": 21,
          "table_chunks": 0,
          "regular_chunks": 11,
          "avg_chunk_quality": 0.6854212454212453,
          "doc_level_quality": 0.7193939393939395
        }
      },
      {
        "tier": 2,
        "model_loaded": true,
        "model_name": "facebook/nllb-200-distilled-1.3B",
        "processing_time_seconds": 701.214889,
        "chunks_found": true,
        "total_chunks": 11,
        "chunks_translated": 21,
        "chunks_english": 0,
        "table_chunks_processed": 0,
        "quality_scores": {
          "overall": 0.7379762157018591,
          "repetition": 1.0,
          "language": 0.9199999999999999,
          "medical": 0.3566738816738818,
          "artifacts": 0.9984490257054599,
          "coherence": 1.0,
          "chunk_count": 21,
          "table_chunks": 0,
          "regular_chunks": 11,
          "avg_chunk_quality": 0.6945448514234641,
          "doc_level_quality": 0.8393160656847809
        }
      }
    ],
    "final_tier_used": 2,
    "final_model_used": "facebook/nllb-200-distilled-1.3B",
    "retranslation_occurred": true,
    "quality_comparison": {
      "tier_1_overall": 0.6956130536130535,
      "tier_2_overall": 0.7379762157018591,
      "improvement": 0.04236316208880564
    },
    "final_quality_scores": {
      "overall": 0.7379762157018591,
      "repetition": 1.0,
      "language": 0.9199999999999999,
      "medical": 0.3566738816738818,
      "artifacts": 0.9984490257054599,
      "coherence": 1.0,
      "chunk_count": 21,
      "table_chunks": 0,
      "regular_chunks": 11,
      "avg_chunk_quality": 0.6945448514234641,
      "doc_level_quality": 0.8393160656847809
    },
    "chunks_translated": 13,
    "chunks_preserved_english": 8,
    "table_chunks_processed": 1,
    "total_processing_time_seconds": 865.336646,
    "translation_strategy": "hierarchical_medical_optimized",
    "medical_preservation_used": "dynamic_pattern_based",
    "table_content_detected": 0,
    "tier_1_available": true,
    "tier_2_available": true,
    "translation_decision": "tier_2_better_than_tier_1",
    "processing_completed_timestamp": "2025-08-01T08:32:37.881789"
  }
}